EN | FR
Search
Close this search box.
EN | FR
Search

Modelling Fibrotic Lung Diseases

» 

Panel Discussion

Emka & SCIREQ hosted a free in-person panel discussion on May 17th from 7:00 to 8:30am PST. The event was held at the Clift Royal Sonesta Hotel in the Applegarth room. 

Experts at the forefront of pulmonary fibrosis research discussed Modelling Fibrotic Lung Diseases. We hoped to shed light on: 

  • The various methods of developing a fibrotic model in small animals.
  • The implications of the model generation.
  • Best practices for new labs.
 

The event is available to watch after filling out the form.

The summary document is also available to be downloaded here.

Learn more about the panelists:

DR. ELIZABETH REDENTE – NATIONAL JEWISH HEALTH

Dr. Redente’s lab focuses on the interactions between TNF-α, macrophages and myofibroblasts and their role in the resolution of established pulmonary fibrosis with the goal to investigate the mechanisms by which TNF-α resolves fibrosis as the basis for the translational application of this work as a potential therapeutic. Learn more about Dr. Redente here.

DR. CLAUDE LE SAUX – UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

Dr. Le Saux studies how senescent cells regulate fibrogenesis and its resolution. Switching their secretory phenotype factors expression over time, dynamic changes in the secretory phenotype from profibrotic to pro-resolution occurs in skin but not in lungs. Learn more about her lab here.

DR. ANNETTE ROBICHAUD – SCIREQ INC.

The measurement of lung function is Dr Robichaud’s main area of interest. Throughout the years, she has acquired extensive experience and scientific expertise in this field. Her focus is to empower scientists to generate sound and reproducible research through the development of sophisticated instruments, automated processes, and innovative techniques. 

Agenda

Introduction: SCIREQ will kick off the event and each panelist will introduce themselves and provide a quick summary of their current research.

Panel discussion focused on preclinical models of fibrotic lung disease.

Question and answer period.

Closing remarks.